FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321749323> ?p ?o ?g. }

• W4321749323 endingPage "601" @default.
• W4321749323 startingPage "592" @default.
• W4321749323 abstract "Background Limited information exists regarding the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with CKD treated in routine care. We evaluated the safety of SGLT2i in patients with CKD and type 2 diabetes treated in US routine practice. Methods Using claims data from Medicare and two large US commercial databases (April 2013–December 2021), we included 96,128 adults with CKD stages 3–4 and type 2 diabetes who newly filled prescriptions for SGLT2i versus glucagon-like peptide-1 receptor agonists (GLP-1RA). Safety outcomes included diabetic ketoacidosis (DKA), lower limb amputations, nonvertebral fractures, genital infections, hypovolemia, AKI, hypoglycemia, and severe urinary tract infections (UTIs). Hazard ratios (HRs) and incidence rate differences per 1000 person-years were estimated after 1:1 propensity score matching, adjusted for >120 baseline characteristics. Results Compared with GLP-1RA, SGLT2i initiators had a higher risk of nonvertebral fractures (HR, 1.30 [95% confidence interval (CI), 1.03 to 1.65]; incidence rate difference, 2.13 [95% CI, 0.28 to 3.97]), lower limb amputations (HR, 1.65 [95% CI, 1.22 to 2.23]; incidence rate difference, 2.46 [95% CI, 1.00 to 3.92]), and genital infections (HR, 3.08 [95% CI, 2.73 to 3.48]; incidence rate difference, 41.26 [95% CI, 37.06 to 45.46]). Similar risks of DKA (HR, 1.07 [95% CI, 0.74 to 1.54]; incidence rate difference, 0.29 [95% CI, −0.89 to 1.46]), hypovolemia (HR, 0.99 [95% CI, 0.86 to 1.14]; incidence rate difference, 0.20 [95% CI, −2.85 to 3.25]), hypoglycemia (HR, 1.08 [95% CI, 0.92 to 1.26]; incidence rate difference, 1.46 [95% CI, −1.31 to 4.23]), and severe UTI (HR, 1.02 [95% CI, 0.87 to 1.19]; incidence rate difference, 0.35 [95% CI, −2.51 to 3.21]) were observed. SGLT2i had lower risk for AKI (HR, 0.93 [95% CI, 0.87 to 0.99]; incidence rate difference, −6.75 [95% CI, −13.69 to 0.20]). Conclusions In US patients with CKD and type 2 diabetes receiving routine care, SGLT2i use was associated with higher risks of genital infections and potentially lower limb amputations and nonvertebral fractures." @default.
• W4321749323 created "2023-02-25" @default.
• W4321749323 creator A5022334158 @default.
• W4321749323 creator A5029305012 @default.
• W4321749323 creator A5044474781 @default.
• W4321749323 creator A5076997901 @default.
• W4321749323 creator A5085331349 @default.
• W4321749323 date "2023-02-24" @default.
• W4321749323 modified "2023-09-27" @default.
• W4321749323 title "Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study" @default.
• W4321749323 cites W132780861 @default.
• W4321749323 cites W1849521086 @default.
• W4321749323 cites W1978649184 @default.
• W4321749323 cites W1981482970 @default.
• W4321749323 cites W1993759402 @default.
• W4321749323 cites W2043090471 @default.
• W4321749323 cites W2049491523 @default.
• W4321749323 cites W2052957337 @default.
• W4321749323 cites W2057847137 @default.
• W4321749323 cites W2078346178 @default.
• W4321749323 cites W2087018232 @default.
• W4321749323 cites W2089481021 @default.
• W4321749323 cites W2107651010 @default.
• W4321749323 cites W2108529411 @default.
• W4321749323 cites W2114598208 @default.
• W4321749323 cites W2126049444 @default.
• W4321749323 cites W2126332577 @default.
• W4321749323 cites W2155749392 @default.
• W4321749323 cites W2158197611 @default.
• W4321749323 cites W2169946604 @default.
• W4321749323 cites W2602058707 @default.
• W4321749323 cites W2615714795 @default.
• W4321749323 cites W2624032915 @default.
• W4321749323 cites W2626446274 @default.
• W4321749323 cites W2771285175 @default.
• W4321749323 cites W2773101798 @default.
• W4321749323 cites W2891073947 @default.
• W4321749323 cites W2892145330 @default.
• W4321749323 cites W2894993577 @default.
• W4321749323 cites W2939222610 @default.
• W4321749323 cites W2966426030 @default.
• W4321749323 cites W2984119658 @default.
• W4321749323 cites W2999223678 @default.
• W4321749323 cites W3042176300 @default.
• W4321749323 cites W3046159964 @default.
• W4321749323 cites W3047536039 @default.
• W4321749323 cites W3080635855 @default.
• W4321749323 cites W3088173406 @default.
• W4321749323 cites W3112788101 @default.
• W4321749323 cites W3120821309 @default.
• W4321749323 cites W3134769649 @default.
• W4321749323 cites W3193155753 @default.
• W4321749323 cites W3195404919 @default.
• W4321749323 cites W4200141909 @default.
• W4321749323 cites W4200340161 @default.
• W4321749323 cites W4205782428 @default.
• W4321749323 cites W4206404428 @default.
• W4321749323 cites W4253996779 @default.
• W4321749323 cites W4281637959 @default.
• W4321749323 cites W4306783500 @default.
• W4321749323 cites W4308183941 @default.
• W4321749323 doi "https://doi.org/10.2215/cjn.0000000000000115" @default.
• W4321749323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36827225" @default.
• W4321749323 hasPublicationYear "2023" @default.
• W4321749323 type Work @default.
• W4321749323 citedByCount "2" @default.
• W4321749323 countsByYear W43217493232023 @default.
• W4321749323 crossrefType "journal-article" @default.
• W4321749323 hasAuthorship W4321749323A5022334158 @default.
• W4321749323 hasAuthorship W4321749323A5029305012 @default.
• W4321749323 hasAuthorship W4321749323A5044474781 @default.
• W4321749323 hasAuthorship W4321749323A5076997901 @default.
• W4321749323 hasAuthorship W4321749323A5085331349 @default.
• W4321749323 hasConcept C120665830 @default.
• W4321749323 hasConcept C121332964 @default.
• W4321749323 hasConcept C126322002 @default.
• W4321749323 hasConcept C134018914 @default.
• W4321749323 hasConcept C167704817 @default.
• W4321749323 hasConcept C207103383 @default.
• W4321749323 hasConcept C2777180221 @default.
• W4321749323 hasConcept C2777422806 @default.
• W4321749323 hasConcept C2779306644 @default.
• W4321749323 hasConcept C2781283889 @default.
• W4321749323 hasConcept C2908647359 @default.
• W4321749323 hasConcept C44249647 @default.
• W4321749323 hasConcept C555293320 @default.
• W4321749323 hasConcept C61511704 @default.
• W4321749323 hasConcept C71924100 @default.
• W4321749323 hasConcept C90924648 @default.
• W4321749323 hasConcept C99454951 @default.
• W4321749323 hasConceptScore W4321749323C120665830 @default.
• W4321749323 hasConceptScore W4321749323C121332964 @default.
• W4321749323 hasConceptScore W4321749323C126322002 @default.
• W4321749323 hasConceptScore W4321749323C134018914 @default.
• W4321749323 hasConceptScore W4321749323C167704817 @default.
• W4321749323 hasConceptScore W4321749323C207103383 @default.
• W4321749323 hasConceptScore W4321749323C2777180221 @default.
• W4321749323 hasConceptScore W4321749323C2777422806 @default.

• next